Proactive Investors - Run By Investors For Investors

MGC Pharmaceuticals attracts $5 million for medical cannabis facility in Malta

Cannabis produced at the facility to be used in the production of GMP-grade pharmaceutical products.
a cannabis plant
Awarded full medical cannabis production and cultivation contract

MGC Pharmaceuticals Ltd (ASX:MXC) has successfully raised over $5 million via a share placement to sophisticated and professional investors at 7 cents per share.

The oversubscribed placement received strong support from new and existing shareholders and was cornerstoned by the Merchant Opportunities Fund.

New medical cannabis production facility in Malta

MGC will use the new funds to contribute to the construction of a fully-licensed medical cannabis facility in Malta.

The company has been awarded a contract by the government of Malta to construct a 4,000 square metre state-of-the-art medical cannabis production and cultivation facility.

MGC is one of only five companies, and the only company from Australia, to be awarded a full medical cannabis production and cultivation contract, following a competitive tender process.

Cannabis-based pharmaceutical products for global markets

Under the agreement, the company will be permitted to produce all THC (tetrahydrocannabinol) and CBD (cannabidiol) strains of medical cannabis.

This will expand the commercial opportunity for MGC to develop additional medical cannabis pharmaceutical products into key European and global markets.

Cannabis produced at the facility will be used by MGC in the production of its GMP-grade pharmaceutical products for global markets including Australia.

The facility is also expected to enable the supply of medical cannabis flowers directly into the emerging European markets, including Germany.

Changes to Malta’s medical cannabis laws

The Malta contract terms require MGC to spend a minimum of about US$6.5 million over the first three years on the construction and operations of the medical cannabis facility.

The contract terms will be governed under the final legislative changes to Malta’s medical cannabis laws which are currently in final stages of a parliamentary process.

READ: MGC Pharmaceuticals commencing production of CannEpil for epilepsy

MGC recently commenced production of its first batch of CannEpil at its European medicinal cannabis facility.

CannEpil is MGC’s first pharmaceutical-grade medical cannabis product targeting people with drug-resistant epilepsy.

Once the distribution of CannEpil commences, it is expected to generate more than $1 million in annual sales in the Australian market in its first year.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full MXC profile View Profile

MGC Pharmaceuticals Ltd Timeline

Related Articles

1541165310_canadian-flag-1.jpg
November 03 2018
Back Home Medical Cannabis Corp has agreed on a 24,000-kilogram three-year production and supply agreement
Cannabis leaf
November 19 2018
With the legalisation of recreational cannabis in Canada in October, and the US expected to follow suit, the company has its sights set on building up the very best in the industry
1540909388_Marijuana-stethoscope.jpg
October 31 2018
The firm wants to become the first publicly listed, globally focused, pure cannabis company

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use